KingMed Diagnostics forecasts significant half-year loss for 2025

Guangzhou KingMed Diagnostics Group expects a net loss of 65-95 million yuan for the first half of 2025, compared to a 89.65 million yuan profit in the prior year.

The anticipated loss stems from slower business development, decreased operating leverage due to high fixed costs, and credit impairment losses of 260-290 million yuan from extended accounts receivable collection.